Central Nervous System Tumors.TPS2573 Journal of Clinical Oncology -published online before print May 25, 2020.
Alliance A071701: Genomically guided treatment trial in brain metastases.
Priscilla Kaliopi Brastianos.
"There will be 21 evaluable patients assigned to each of the CDK and PI3K inhibitor and tumor type cohorts (breast, lung and other) and 10 patients assigned to the NTRK/ROS1 inhibitor cohort (lung) for a total of 136 evaluable patients.
Although current systemic therapy for brain metastases is often ineffective, we hypothesize that targeted therapies will demonstrate efficacy in patients harboring the appropriate mutations."
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.TPS2573
Paxalisib - Pi3K inhibitor will be used for 63 patients.ie. (21 evaluable patients for breast), (21 for lung), and (21 for other).
abemaciclib - CDK inhibitor will be used for 63 patients ie. (21 evaluable patients for breast), (21 for lung), and (21 for other).
entrectinib - NTRK/ROS1 inhibitor will be used for 10 patients. ie (10 evaluable patients for lung).
Total of 136 evaluable patients.
Dr P Brastianos has reallocated 46% of the trial patients to use Paxalisib, together with her hypothesis mentioned above.
I am excited about the Abstract, but will have to wait until interim trial data is presented.
Regards.
